236 related articles for article (PubMed ID: 35953673)
1. High-fidelity Cas13 variants for targeted RNA degradation with minimal collateral effects.
Tong H; Huang J; Xiao Q; He B; Dong X; Liu Y; Yang X; Han D; Wang Z; Wang X; Ying W; Zhang R; Wei Y; Xu C; Zhou Y; Li Y; Cai M; Wang Q; Xue M; Li G; Fang K; Zhang H; Yang H
Nat Biotechnol; 2023 Jan; 41(1):108-119. PubMed ID: 35953673
[TBL] [Abstract][Full Text] [Related]
2. Negative autoregulation mitigates collateral RNase activity of repeat-targeting CRISPR-Cas13d in mammalian cells.
Kelley CP; Haerle MC; Wang ET
Cell Rep; 2022 Aug; 40(7):111226. PubMed ID: 35977479
[TBL] [Abstract][Full Text] [Related]
3. The double life of CRISPR-Cas13.
Bot JF; van der Oost J; Geijsen N
Curr Opin Biotechnol; 2022 Dec; 78():102789. PubMed ID: 36115160
[TBL] [Abstract][Full Text] [Related]
4. Insights Gained from RNA Editing Targeted by the CRISPR-Cas13 Family.
Liu L; Pei DS
Int J Mol Sci; 2022 Sep; 23(19):. PubMed ID: 36232699
[TBL] [Abstract][Full Text] [Related]
5. Collateral activity of the CRISPR/RfxCas13d system in human cells.
Shi P; Murphy MR; Aparicio AO; Kesner JS; Fang Z; Chen Z; Trehan A; Guo Y; Wu X
Commun Biol; 2023 Mar; 6(1):334. PubMed ID: 36977923
[TBL] [Abstract][Full Text] [Related]
6. Structure and engineering of the minimal type VI CRISPR-Cas13bt3.
Nakagawa R; Kannan S; Altae-Tran H; Takeda SN; Tomita A; Hirano H; Kusakizako T; Nishizawa T; Yamashita K; Zhang F; Nishimasu H; Nureki O
Mol Cell; 2022 Sep; 82(17):3178-3192.e5. PubMed ID: 36027912
[TBL] [Abstract][Full Text] [Related]
7. Cas13d: A New Molecular Scissor for Transcriptome Engineering.
Gupta R; Ghosh A; Chakravarti R; Singh R; Ravichandiran V; Swarnakar S; Ghosh D
Front Cell Dev Biol; 2022; 10():866800. PubMed ID: 35433685
[TBL] [Abstract][Full Text] [Related]
8. A New Method for Programmable RNA Editing Using CRISPR Effector Cas13X.1.
Li L; Liu W; Zhang H; Cai Q; Wen D; Du J; Sun J; Li L; Gao C; Lin P; Wu M; Jiang J
Tohoku J Exp Med; 2023 May; 260(1):51-61. PubMed ID: 36823185
[TBL] [Abstract][Full Text] [Related]
9. Intrinsic targeting of host RNA by Cas13 constrains its utility.
Li Z; Li Z; Cheng X; Wang S; Wang X; Ma S; Lu Z; Zhang H; Zhao W; Chen Z; Yao Y; Zhang C; Chao L; Li W; Fei T
Nat Biomed Eng; 2024 Feb; 8(2):177-192. PubMed ID: 37872368
[TBL] [Abstract][Full Text] [Related]
10. Low copy CRISPR-Cas13d mitigates collateral RNA cleavage.
Hart SK; Wessels HH; Méndez-Mancilla A; Müller S; Drabavicius G; Choi O; Sanjana NE
bioRxiv; 2024 May; ():. PubMed ID: 38798586
[TBL] [Abstract][Full Text] [Related]
11. Optimization of specific RNA knockdown in mammalian cells with CRISPR-Cas13.
Burris BJD; Molina Vargas AM; Park BJ; O'Connell MR
Methods; 2022 Oct; 206():58-68. PubMed ID: 35987443
[TBL] [Abstract][Full Text] [Related]
12. CRISPR/Cas13 effectors have differing extents of off-target effects that limit their utility in eukaryotic cells.
Ai Y; Liang D; Wilusz JE
Nucleic Acids Res; 2022 Jun; 50(11):e65. PubMed ID: 35244715
[TBL] [Abstract][Full Text] [Related]
13. Orthogonal inducible control of Cas13 circuits enables programmable RNA regulation in mammalian cells.
Ding Y; Tous C; Choi J; Chen J; Wong WW
Nat Commun; 2024 Feb; 15(1):1572. PubMed ID: 38383558
[TBL] [Abstract][Full Text] [Related]
14. CRISPR-Cas13d mediates robust RNA virus interference in plants.
Mahas A; Aman R; Mahfouz M
Genome Biol; 2019 Dec; 20(1):263. PubMed ID: 31791381
[TBL] [Abstract][Full Text] [Related]
15. Engineered Cas13 variants with minimal collateral RNA targeting.
Nat Biotechnol; 2023 Jan; 41(1):29-30. PubMed ID: 35962198
[No Abstract] [Full Text] [Related]
16. Applications of CRISPR/Cas13-Based RNA Editing in Plants.
Kavuri NR; Ramasamy M; Qi Y; Mandadi K
Cells; 2022 Aug; 11(17):. PubMed ID: 36078073
[TBL] [Abstract][Full Text] [Related]
17. CRISPR-Cas13 System as a Promising and Versatile Tool for Cancer Diagnosis, Therapy, and Research.
Palaz F; Kalkan AK; Can Ö; Demir AN; Tozluyurt A; Özcan A; Ozsoz M
ACS Synth Biol; 2021 Jun; 10(6):1245-1267. PubMed ID: 34037380
[TBL] [Abstract][Full Text] [Related]
18. The collateral activity of RfxCas13d can induce lethality in a RfxCas13d knock-in mouse model.
Li Y; Xu J; Guo X; Li Z; Cao L; Liu S; Guo Y; Wang G; Luo Y; Zhang Z; Wei X; Zhao Y; Liu T; Wang X; Xia H; Kuang M; Guo Q; Li J; Chen L; Wang Y; Li Q; Wang F; Liu Q; You F
Genome Biol; 2023 Feb; 24(1):20. PubMed ID: 36726140
[TBL] [Abstract][Full Text] [Related]
19. A one-step platform for screening high-efficient and minimal off-target CRISPR/Cas13 crRNAs to eradicate SARS-CoV-2 virus for treatment of COVID-19 patients.
Li PY; Li SQ; Gao SG; Dong DY
Med Hypotheses; 2022 Feb; 159():110754. PubMed ID: 35002020
[TBL] [Abstract][Full Text] [Related]
20. Alleviation of neurological disease by RNA editing.
Zhang S; Chen L; Zhang Y; Fang D
Methods; 2021 Oct; 194():94-99. PubMed ID: 33933604
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
